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Abstract
Background: Benzodiazepines carry the risk of inducing cognitive impairments, which may go unnoticed while
profoundly disturbing social activity. Furthermore, these impairments are partly associated with the elimination half-
life (EH) of the substance from the body. The object of the present study was to examine the effects of etizolam
and ethyl loflazepate, with EHs of 6 h and 122 h, respectively, on information processing in healthy subjects.
Methods: Healthy people were administered etizolam and ethyl loflazepate acutely and subchronically (14 days).
The auditory P300 event-related potential and the neuropsychological batteries described below were employed to
assess the effects of drugs on cognition. The P300 event-related potential was recorded before and after drug
treatments. The digit symbol test, trail making test, digit span test and verbal paired associates test were
administered to examine mental slowing and memory functioning.
Results: Acute administration of drugs caused prolongation in P300 latency and reduction in P300 amplitude.
Etizolam caused a statistically significant prolongation in P300 latency compared to ethyl loflazepate. Furthermore,
subchronic administration of etizolam, but not ethyl loflazepate, still caused a weak prolongation in P300 latency.
In contrast, neuropsychological tests showed no difference.
Conclusions: The results indicate that acute administration of ethyl loflazepate induces less effect on P300 latency
than etizolam.
Background
Benzodiazepines have anxiolytic, sedative, anticonvulsant
and myorelaxant properties, and have been widely pre-
scribed in various clinical settings. These compounds,
however, also induce adverse effects such as overseda-
tion, cognitive impairment, motor impairment and with-
drawal. These adverse effects may be partly associated
with the elimination half-life (EH) of the compounds
from the body; that is, long-term use of the compounds
with a short elimination rate may induce withdrawal
syndromes, whereas accumulation-related effects of a
long elimination rate may include oversedation, cogni-
tive dysfunction and motor impairment [1-4].
It has been observed previously that cognitive impair-
ment induced by benzodiazepines may go unnoticed
while profoundly disturbing social activity [5]. Therefore,
it is clinically very important to take note of the cognitive
effects of benzodiazepines. In order to assess the effects
of benzodiazepines on cognition, the event-related poten-
tial (ERP), P300, may be useful [6], as well as neuropsy-
chological tests. The P300 components of ERP are
elicited by an auditory oddball paradigm in which a sub-
ject detects infrequent task-relevant stimuli randomly
presented among frequent stimuli. P300 reflects stimulus
context and stimulus meaning [7]. P300 components are
associated with cognitive processes such as attention,
memory, orientation and evaluation. Relationships
between P300 and neuropsychological function have
been reported [8-14]. Benzodiazepine anxiolytic drugs, as
well as benzodiazepine hypnotic drugs, have been
reported to induce reductions in P300 amplitude and
prolongation in P300 latency [6,15-20].
As far as is known, however, there are no reports on
the effects of chronic or subchronic administration of
benzodiazepines on cognition and P300 from the view-
point of elimination rates. Here, we studied the effects
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functions and P300 components of auditory ERP under
acute and subchronic administration of ethyl loflazepate
and etizolam. Ethyl loflazepate is a potent, non-sedative,
anxiolytic drug with a long EH of 122 h [21], whereas
etizolam is characteristic of a potent antianxiety and
sedative drug with a short EH of 6 h [22]. Therefore,
etizolam is often used as a sleep inducer. However, it is
well known that benzodiazepine drugs including etizo-
lam and ethyl loflazepate have the effects of reducing
the deep sleep stage 3, resulting in loss of good sleep.
T h ea i mo ft h ep r e s e n ts t u d yi st oe x a m i n ew h e t h e r
sedative or anxiolytic actions of benzodiazepines have
some effects on ERP and neuropsychological tests.
Methods
Study design and subjects
All subjects had normal acoustic function and were
right handed. The ethics committee of Chiba University
Graduate School of Medicine approved the experiments.
Subjects were free from treatment for past psychiatric
illness. Written informed consent was obtained after the
procedure had been fully explained.
In the acute experiment, 10 healthy men (n = 5) and
women (n = 5) ranging in age from 16 to 38 (average age
28.6 (SD 6.5)) participated in the study. First, all subjects
were measured for the P300 components of ERP and
received neuropsychological tests. Then they took etizo-
l a m( 1o r2m g ,o r a l l y ) .T h e n ,2hl a t e r ,t h es a m eE R P
and neuropsychological tests were performed, since the
blood concentration of the drugs reaches a maximum 1-2
h after consumption. After a 2-week washout period, the
same experimental procedures were repeated, but sub-
jects took ethyl loflazepate (1 or 2 mg, orally).
In the subchronic experiment, 17 healthy men (n = 8)
and women (n = 9) ranging in age from 22 to 34 (aver-
age age 27.4 (SD 4.1)) participated in the study. The 17
subjects were divided into 2 groups: the first group was
given etizolam (1 mg, orally, for 14 days), and the sec-
ond given ethyl loflazepate (1 mg, orally for 14 days).
Subjects were asked to take drugs in the evening every
day, and performed ERP recording and neuropsychologi-
cal tests 14-20 h after taking the last drug. Subjects per-
formed ERP recording and neuropsychological tests
twice before and after subchronic treatment with etizo-
lam or ethyl loflazepate.
Doses examined in the present study were chosen
based on the equivalent conversion table for anxiolytic
d r u g s( 5m go fd i a z e p a m ,1 . 5m go fe t i z o l a m ,a n d1 . 6 7
mg of ethyl loflazepate) [23,24].
ERP procedure
Electroencephalogram electrodes were attached at Fz, Cz
and Pz according to the international 10-20 system.
Earlobe electrodes were linked for reference. Electro-
oculography was also recorded from vertical and lateral
derivations to check ocular artefacts. Subjects sat on a
semi-reclined chair in a sound-attenuated and electri-
cally shielded room during recordings. Subjects were
instructed to press a button as quickly as possible upon
hearing the infrequent high-pitched tones. Event-related
potentials were recorded under an oddball paradigm.
The stimuli consisted of a 1,000 Hz tone burst (frequent
non-target stimulus) and a 2,000 Hz tone burst (rare
target stimulus). In each paradigm, 200 stimuli were
presented through bilateral earphones by using a Neuro-
pack 10 (MEB-2200, Nihon Kohden, Tokyo, Japan). The
ratio of the rare versus frequent stimuli was 0.25. Sti-
muli were presented in a random order, the duration of
each stimulus being 120 ms, with rise and fall times of
10 ms. The intensity was 40 dB for all stimuli. The
interstimulus interval was 1.5 s.
Neuropsychological tests
The trail making test consists of two parts [25]. In part
A, subjects are asked to draw lines connecting 25 conse-
cutively numbered circles on a worksheet. In part B,
they draw lines connecting 25 consecutively numbered
and lettered circles, alternating between the sequences
(for example, 1-A-2-B-3 and so on). Part A examines
psychomotor speed and attention. Part B examines set
alternation or divided attention.
The digit symbol modalities test is a measure of
switching attention [26]. Subjects are asked to identify
nine different symbols corresponding to the numbers 1
through 9, and write the correct number under the cor-
responding symbol. Thus, visual shifting and pairing of
specific digits is directed, with a set of prespecified
symbols.
The forward digit span test is a measure of simple
attention, immediate memory and attentional control
processing. In contrast, backward digit span is not only
a test of attentional control processing but also working
memory test.
The verbal paired associates test from the Wechsler
Memory Scale-Revised (WMS-R) is a cued recall test of
verbal memory [27]. Subjects learned a list of eight ver-
bal paired associates. Then, either immediately or after a
delay, the examiner says one word of each pair and the
subjects recall the other word. Three sets of immediate
memory testing and one set of delayed recall testing
were administered.
Statistical analysis
Two-way repeated measures analysis of variance
(ANOVA) was performed to assess the overall differences
between variables. Where a significant interaction in the
within-subject variables was found, subsequent one-way
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by a post hoc comparison using Fisher’s protected least
significant difference test. For comparison of the mean
values between the two groups, statistical evaluation was
performed using the two-tailed Student’stt e s t .T h es i g -
nificance level was set at P < 0.05.
Results
Effects of acute treatments with etizolam and ethyl
loflazepate on P300
For acute drug treatment on the P300, two-way repeated
ANOVA indicated significant effects of treatment (Fz, F
(1,16) = 49.397, P < 0.0001; Cz, F (1,16) = 59.022, P <
0.0001; Pz, F (1,16) = 45.623, P < 0.0001), but not effects
of group, on latency, with a significant interaction (Fz,
treatment × group, F (3,16) = 3.846, P = 0.0301; Cz,
treatment × group, F (3,16) = 3.436, P = 0.0423; Pz,
treatment × group, F (3,16) = 3.278, P = 0.0483) (Figure
1a-c). The subsequent one-way ANOVA on the changes
of P300 latency indicated significant differences (Fz, F
(3,16) = 3.431, P = 0.0425; Cz, F (3,16) = 3.436, P =
0.0423; Pz, F (3,16) = 3.387, P = 0.0441), and the post
hoc comparison using Fisher’s protected least significant
difference test indicated the following: ethyl loflazepate
1 mg has less effects than etizolam 1 mg and etizolam 2
mg in Fz (Figure 1g), Cz (Figure 1h), and Pz (Figure 1i).
For amplitude, two-way repeated ANOVA indicated sig-
nificant effects of treatment (Cz, F (1,16) = 7.967, P =
0.0123; Pz, F (1,16) = 8.807, P = 0.0091; but see Fz, F
(1,16) = 4.032, P = 0.0618), but not effects of group,
without a significant interaction (Figure 1d-f). This
seems to reflect that benzodiazepine reduced P300
amplitude. Although the subsequent one-way ANOVA
on the changes of P300 amplitude revealed no signifi-
cant difference among drug groups (Figure 1j-l), the
magnitude of changes showed that etizolam (2 mg) pro-
duced a trend in reduction of amplitude.
Effects of subchronic treatments with etizolam and ethyl
loflazepate on P300
For subchronic drug treatment on the P300, two-way
repeated ANOVA indicated significant effects of treat-
ment region specifically (Fz, F (1,15) = 7.734, P = 0.0140;
but see Cz, F (1,15) = 2.391, P = 0.1491; Pz, F (1,15) =
Figure 1 Effects of acute treatments with etizolam and ethyl loflazepate on P300.* P < 0.05, **P < 0.01, ***P <0 . 0 0 1c o m p a r e dt o
pretreatment (repeated analysis of variance (ANOVA)). (a) Trend for changes without significance. *P < 0.05, **P < 0.01 compared to ethyl
loflazepate with low dose (1 mg) (ANOVA followed by Fisher’s protected least significant difference test).
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without a significant interaction (Figure 2a-c). The subse-
quent Student t test on the changes of P300 latency
revealed no significant difference between two drugs
(Figure 2g-i). With regard to amplitude, two-way
repeated ANOVA indicated no significant effects of treat-
ment without a significant interaction (Figure 2d-f, j-l).
Effects of treatments with etizolam and ethyl loflazepate
on neuropsychological tests
For acute effects of drug treatment on neuropsychologi-
cal tests, two-way repeated ANOVA showed significant
practice effects of repeated testing, but not effects of
drug group, on test scoring without a significant interac-
tion in some tests including trail making A (F (1,16) =
7.399, P = 0.0151, Figure 3a), trail making B (F (1,16) =
8.409, P = 0.0104, Figure 3b), digit span forward (F
(1,16) = 8.696, P = 0.0094, Figure 3c), verbal paired
associates immediate memory (F(1,16) = 6.485, P =
0.0215, Figure 3e) and digit symbol (F(1,16) = 24.209, P
= 0.0002, Figure 3g), and no significant effects of
repeated testing and drugs on test scoring without a sig-
nificant interaction in other tests such as digit span
backward (Figure 3d) and verbal paired associates
delayed recall (Figure 3f).
For subchronic effects of drug treatment on neuropsy-
chological tests, two-way repeated ANOVA indicated
significant practice effects of repeated testing, but not
effects of drug group, on test scoring without a signifi-
cant interaction, in some tests including trail making
test A (F (1,15) = 12.472, P = 0.0030, Figure 3h), trail
making test B (F (1,15) = 5.426, P = 0.0342, Figure 3i),
digit span forward (F (1,15) = 7.092, P = 0.0177, Figure
3j), verbal paired associates immediate memory (F (1,15)
= 16.449, P = 0.0010, Figure 3l), verbal paired associates
delayed recall (F (1,15) = 5.773, P = 0.0297, Figure 3m)
and digit symbol (F (1,15) = 6.075, P = 0.0236, Figure
3n), and no significant effects of repeated testing and
drug group on test scoring without a significant interac-
tion in digit span backward test (Figure 3k).
Discussion
Our results show acute drug treatment induced prolon-
gation in P300 latency. This is consistent with previous
studies demonstrating that benzodiazepines such as
alprazolam, lorazepam, clonazepam and triazolam
induce prolongation in P300 latency [6,16,18,19]. How-
ever, subsequent ANOVA revealed that etizolam (1 and
2 mg) induced significant prolongation in P300 latency
compared to ethyl loflazepate (1 mg). The difference
Figure 2 Effects of subchronic treatments with etizolam and ethyl loflazepate on P300.* P < 0.05 compared to pretreatment (repeated
analysis of variance (ANOVA)).
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pate could contribute to the potent sedative effects of
etizolam, although equivalent doses of these two drugs
to diazepam are clinically almost the same. P300 latency
is suggested to reflect the stimulus evaluation time, and
is relatively independent of response selection and
execution [28-30]. Therefore, it is conceivable that ethyl
loflazepate has less effect on P300-related information
processing, although the subjects did not exhibit any
harmful effects on motor skills, visuomotor tracking
speed, and delayed memory in the neuropsychological
tests.
Secondly, subchronic treatment with drugs produced
prolongation in P300 latency only in the Fz regions.
Weak prolongation in P300 latency was seen in the eti-
zolam-treated subjects (although this was not statisti-
cally significant). The magnitude of prolongation by
subchronic ethizolam treatment was reduced when com-
pared to the acute administration of etizolam. In sup-
port of this finding, previous studies reported that
people develop tolerance to the sedative and cognitive
effects of benzodiazepines after subchronic treatments
[1]. Interestingly, subchronic treatment of ethyl loflaze-
pate did not prolong the latency in spite of its long
elimination rate.
Finally, acute but not subchronic treatment with ben-
zodiazepine reduced P300 amplitude. Based on the mag-
nitude of changes, the main effects on the reduction of
P300 amplitude were produced by etizolam (2 mg). This
result replicated previous studies that benzodiazepine
anxiolytic drugs (lorazepam, clonazepam and alprazo-
lam) induced reductions in P300 amplitude [15,17].
Recent studies demonstrated that reduction in auditory
P300 amplitude correlated with the severity of thought
disorders [31,32]. Previous studies reported that a single
administration of a benzodiazepine drug produced
impairment of learning and memory [1-3]. However, the
present study showed no aversive effects of the exam-
ined drugs on neuropsychological tasks such as atten-
tion-needed tasks (trails making test, digit span) and
memory (verbal paired associates, digit symbol). Since
t h es u b j e c t sw e r ef r e ef r o ma b n o r m a lp a t h o l o g i c a l
Figure 3 Effects of acute and subchronic treatment with etizolam and ethyl loflazepate on neuropsychological tests.
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zolam, not by symptom alleviation due to etizolam.
Differences in the effects on P300 latency between eti-
zolam and ethyl loflazepate could be attributed to their
pharmacological properties, such as sedative effects, and
affinities for ω-1 and ω-2 sites. Etizolam is short acting
(EH of 6 h) whereas ethyl loflazepate is long acting (EH
of 122 h).
With regard to limitations of the present study, the
sample size was small.
Conclusions
Acute administration of etizolam induced significant
prolongation in P300 latency whereas low dose ethyl
loflazepate induced fewer effects on P300 latency in the
Fz, Cz and Pz regions than low-dose etizolam. For a
while, subchronic administration of etizolam, but not
ethyl loflazepate, caused weak prolongation in P300
latency in the Fz but not Cz and Pz regions. In contrast,
acute and chronic administrations of etizolam and ethyl
loflazepate showed no deficits in motor skills, visuomo-
tor tracking speed, and delayed memory on neuropsy-
chological testing.
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